Search Tag: GSK
2022 15 Mar
GlaxoSmithKline plc (GSK) has announced the appointment of six directors to the designate Board of Haleon, the new independent company to be formed following the demerger of the GSK Consumer Healthcare business, expected in July 2022. Haleon will be a new global-leading company in Consumer Health, and is strongly positioned to deliver better...Read more
2021 20 Dec
New world-leader in Consumer Healthcare on track to list in 2022 GlaxoSmithKline plc has announced that Sir Dave Lewis has been appointed as Non-Executive Chair Designate of the new Consumer Healthcare company which will result from the proposed demerger from GSK in 2022. His appointment will take effect from 1st January 2022. As set out...Read more
2021 30 Nov
GSK announced that Phil Dormitzer M.D., Ph.D., will join the company as Global Head of Vaccines R&D on 3 December 2021. Phil will report to Dr Hal Barron, Chief Scientific Officer and President R&D, and join GSK’s R&D Leadership Team, and the Vaccines Leadership Team. Phil will be based in Greater Boston, Massachusetts, US. Phil joins from Pfizer...Read more
2020 20 Apr
Sir Andrew Witty, president of UnitedHealth Group and CEO of Optum and f ormer GlaxoSmithKline (GSK) chief executive , has taken a leave of absence from his current job to join the World Health Organization (WHO) in the agency’s efforts to develop a COVID-19 vaccine. You may also like: Where Does COVID-19 Vaccine Development Stand?...Read more
2019 26 Aug
Lions Health 2019 has offered new insights and discussions on how creativity is being embraced by the healthcare industry. Over two days, Lions Health 2019 offered new insights and fresh ideas on how creativity can be applied to improve healthcare through focussed discussion and knowledge. This year’s agenda included first-of-its-kind creativity covering...Read more
2019 16 Jul
Jonathan Symonds CBE, former CFO of AstraZeneca and Novartis has been appointed to chairman at GlaxoSmithKline in the wake of the pharmaceutical company’s break-up. Symonds is currently overseeing operations at HSBC, and will replace Sir Philip Hampton, non-executive chairman at GlaxoSmithKline for the past four years. Symonds has previously...Read more
2014 10 Sep
Novartis has recently presented data which show that Ultibro, its drug for chronic obstructive pulmonary disease (COPD), is superior in reducing flare-ups as compared to GlaxoSmithKline's blockbuster Seretide. The data is from the Phase III head-to-head LANTERN study that was presented at the European Respiratory Society Congress in Munich....Read more
2014 13 May
GlaxoSmithKline has announced that its innovative heart drug darapladib has failed reduce heart attacks or other major cardiac events in patients suffering acute coronary syndrome. This marks a further disappointment for the heart medicine that has previously failed to pass a late-stage trial for patients with well-treated heart disease. ...Read more